Zanzalintinib as a Multi-Targeted Therapeutic Agent

In This article we focused on the therapeutic potential of Zanzalintinib (XL092) as a multi-targeted tyrosine kinase inhibitor (TKI) with both anti-angiogenic and immunomodulatory properties. It highlights how Zanzalintinib, particularly in combination with immune checkpoint inhibitors (ICIs), may offer a promising strategy for treating various solid tumors by targeting key signaling pathways such as MET and TAM kinases. By reviewing preclinical and clinical data, the article underscores efforts to identify new therapeutic targets and emphasizes the ongoing search for predictive biomarkers that can guide and optimize targeted drug development in oncology.